Viewing Study NCT02002312

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 10:18 PM
Ignite Modification Date: 2026-02-28 @ 7:02 AM
Study NCT ID: NCT02002312
Status: COMPLETED
Last Update Posted: 2015-08-13
First Post: 2013-11-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Sponsor: Radboud University Medical Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Clear Cell Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced Renal Cell Carcinoma View
None Clear Cell Renal Cell Carcinoma (ccRCC) View
None Lutetium-177 View
None Lu-177 View
None girentuximab View
None cG250 View
None Monoclonal Antibody View